
Keywords: سازمان غذا و دارو; anticoagulation; bleeding risk; stroke prevention; AF; atrial fibrillation; b.i.d.; twice daily; CKD; chronic kidney disease; ESRD; end-stage renal disease; FDA; Food and Drug Administration; NOAC; non-vitamin K antagonist oral anticoagulant; TTR; time i